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Abstract
Introduction Bladder carcinoma (B-TCC) is the fifth
most prevalent carcinoma in the United States (US) or
Europe. In addition, B-TCC is the most expensive carci-
noma per patient between diagnosis and death, because of
its 50–80 % recurrence rate. B-TCC is an optimal carci-
noma for which to detect DNA alterations in urine, which
is easily obtainable. Chromosomal aberrations in tumors
have been closely related to the carcinogenesis process.
Material and Methods We developed a highly specific
and sensitive oligo-CGH-array for the diagnosis and fol-
low-up of B-TCC, based on the detection of chromosomal
aberrations in urine samples. One hundred and sixty-four
urine samples were analyzed. The qualitative results,
including chromosomal aberrations, were obtained.
Quantitative results are expressed as a percentage of
chromosomal alterations on the autosomes.
Results From the urine samples, we were able to differ-
entiate B-TCC from non-malignant conditions with an
accuracy of 100 % for patients without history of B-TCC.
For follow-up of B-TCC in clinical practice, at least a dele-
tion (8p; 9p; 9q) or a cut-off of [2 % of chromosomal
imbalance was considered as a positive test. According to our
criteria, 100 % of high-grade tumors were diagnosed, and
the sensitivity to predict positive cystoscopy was 95 %
(specificity 73 %). A cut-off[9 % was a strong signature of
high-grade TCC (odds ratio 53 CI 95 % 7–417; p = 0.0002).
Conclusion We developed a sensitive clinical tool for the
detection of B-TCC using DNA extracted from patient
urine. This tool is also able to identify low-grade B-TCC
and identify high-risk patients harboring a high-grade
disease.
Keywords Transitional cell carcinoma  Bladder 
Cytology  CGH-arrays  Cytogenetics  Markers
Introduction
Bladder transitional cell carcinoma (B-TCC) is the fifth to
seventh most prevalent carcinoma in the United States
(US) or Europe. In the USA, 69,250 new cases of bladder
cancer were diagnosed and an estimated 14,990 deaths
occurred in 2011. Non-muscle-invasive B-TCC has the
highest recurrence rate of any carcinoma. In addition,
B-TCC is the most expensive carcinoma per patient
between diagnosis and death, because of its 50–80 %
recurrence rate. Moreover, progression from a high-grade
non-muscle-invasive cancer to a muscle-invasive cancer
occurs in 10–20 % of cases. In addition, bladder carcinoma
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is the most expensive carcinoma per patient between
diagnosis and death because of its 50–80 % recurrence rate
[1].
The current standard for diagnosing B-TCC that
includes the cytological examination of cells present in
voided urine alone does not provide a safe screening
alternative for cystoscopy because of its low sensitivity
(\30 %), especially for the detection of low-grade tumors.
Consequently, the standard procedure for diagnosing
bladder carcinoma recurrence is flexible cystoscopy.
However, as the sensitivity of cystoscopy is approximately
80 %, some tumors could escape detection, especially in
the case of flat tumors (Tis), justifying the concomitant use
of cytology and the development of fluorescence cystos-
copy [2]. Stenzl et al. [3] reported that the percentage of
lesions missed by standard light cystoscopy but detected
using fluorescent cystoscopy ranged between 10 % (high
grade) and 55 % (atypia). Moreover, in approximately
10 % of cases, B-TCC could be associated with upper
urinary tract tumors, justifying a follow-up using CT-
urography, especially when the cytology is positive and the
cystoscopy is negative. Cystoscopy is an invasive diag-
nostic approach that is unpleasant for the patient, with
iatrogenic risks such as infections. Consequently, the actual
practice of surveillance for patients with superficial bladder
cancer differs substantially from the standards recom-
mended in clinical guidelines [4, 5]. After resection of the
primary tumor, guidelines advocate that patients undergo
such procedures every 3–12 months for at least 5 years in
the case of low-risk disease and for life in the case of high
risk disease [6]. A number of noninvasive tests to detect
urinary non-muscle-invasive B-TCC have been developed
in order to overcome the low sensitivity of cytology and to
reduce the number of irrelevant cystoscopy. Current uri-
nary biomarkers for the detection of non-muscle-invasive
B-TCC have been reviewed by Tomasini et al. [7]. ELISA
tests (BTA stat, BTA TRAK and NMP-22) and cytology-
based tests (ImmunoCyt/uCytTM and UroVysionTM) have
obtained either Food and Drug Administration (FDA)
clearance or approval [7]. Several reports have suggested
the diagnostic utility of genetic (and epigenetic) markers
[8]. Since the work of Sidranskyet al. [9, 10] in 1996, the
detection of genomic or mitochondrial DNA alterations has
been able to provide early detection of B-TCC with a high
sensitivity ([70 %) and specificity ([70 %). Moreover, a
better understanding of the molecular pathways [10–12]
involved in bladder carcinogenesis has led to the devel-
opment of translational molecular analyses [loss of heter-
ozygosity (LOH), hypermethylation of CpG-islands, point
mutations] for diagnostic or prognostic purposes, from
DNA isolated from cells present in voided urine samples.
Aberrations on the 9p, 9q and 8p chromosomal arms are the
most common events identified in non-muscle-invasive
B-TCC using LOH analysis or CGH-arrays [13]. Currently,
it is generally recognized that FGFR3 gene mutations and
low chromosomal instability are associated with non-
aggressive superficial tumors and that high chromosomal
instability and TP53 mutations drive progression to inva-
sive carcinoma. Commercial tests have been developed
based on cells present in voided urine samples or the
analysis of their DNA. The FDA-approved test (Urovy-
sionTM) is based on the detection of aneuploidy for chro-
mosomes 3, 7, and 17 and loss of the 9p21 locus. We and
others have previously shown that the detection of recur-
rent bladder cancer can be improved by DNA analysis
(LOH and DNA CpG-island hypermethylation) from voi-
ded urine. More recently, we have developed a specific and
inexpensive CGH-array [14] that combines diagnostic and
prognostic performance for use in clinical practice. The
array covers, with a high density, the target loci reported to
be frequently gained or deleted in bladder carcinoma and,
with a low density, the entire genome. The aim of this
study was to measure the diagnostic performance of this
urinary marker test to predict positive cystoscopy during
the follow-up of non-invasive B-TCC and to assess its




Patients and sample collection
In a first group, thirty patients were enrolled as controls (no
symptoms of bladder carcinoma, no history of urologic
carcinoma), and they were all explored by cystoscopy for
low urinary tract symptoms related to benign urologic
conditions: 15 women for incontinence (55–75 years old)
and 15 men for benign prostatic hyperplasia (50–80 years
old). BCA-1 and cystoscopy were performed on second
group of 134 patients during their usual follow-up for a
history of non-invasive transitional cell carcinoma of the
bladder. Patients with positive cytology were excluded
because the main application of BCA-1 was to identify
high-risk patients with false-negative cytology. All positive
cystoscopy was completed by biopsy on suspect lesions for
pathological analysis. All of the patients had a computed
tomography urography for \2 years in order to explore
upper urinary tract. The follow-up of patient after BCA-1
was at least one year for all patients. Urine samples were
collected during patient visits or in the morning before any
surgical procedure. Urine samples were collected for all
patients using DNA preservation medium (NorgenTM) in
case of office-based outpatient setting. Urine was spun at
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350 g (1,500 rpm) for 10 min and washed twice with
phosphate-buffered saline and stored at -80 C. DNA was
extracted from pellets using the QIAamp DNA Blood Mini
Kit (Qiagen, Hilden, Germany) according to manufac-
turer’s instructions. Study participants provided written
informed consent, and the study protocol received approval
from the institutional review board.
Comparative genomic hybridization array design
CGH was performed using the BCA–oligo CGH-array (Ar-
rayGenomics, Voisins-le-Bretonneux, France). This array
consists of a glass slide spotted with 60,000 oligonucleotides
(oligo) covering genomic areas known to undergo modifi-
cation in TCC of the urinary tract. The oligonucleotide is a
60-mer oligonucleotide which represents, in all, 56.7 Mb
(2 % of the genome). The microarrays are manufactured
using a proprietary non-contact industrial inkjet printing
process, in which oligo-monomers are deposited uniformly
onto specially prepared glass slides. This in situ synthesis
process prints 60-mer-length oligonucleotide probes, base
by base, from digital sequence files. The precise inkjet pro-
cess enables the delivery of extremely small, accurate vol-
umes of the chemicals to be spotted. This technology,
SurePrint, allows as many as 8 arrays to reside on a single
slide (8 9 60,000).
Labeling
A total of 200 ng of urinary DNA was labeled by random
priming with Cy5, and 200 ng of normal genomic DNA
(Promega, Madison, WI, USA) was marked with Cy3 using
the complete labeling kit BioPrime Total Genomic Label-
ing System (Invitrogen, Carlsbad, CA). Excess labeling
was eliminated using the BioPrime Purification Module
with Purelink (Invitrogen, Carlsbad, CA).
After labeling, the urinary DNA and the normal DNA
were combined with Cot-1 DNA (Invitrogen, Carlsbad,
CA), Agilent 10X Blocking Agent and Agilent 2X
Hybridization Buffer. This mix was then incubated first at
95 C for 3 min and then immediately at 37 C for 30 min.
The labeled DNA was deposited on the gasket slide, on
which the BAC–oligo spotted slide was then placed. The
hybridization was performed at 65 C for 18 h. The BCA–
oligo slide was washed with two solutions: wash buffer 1
for 5 min at room temperature and wash buffer 2 for 1 min
at 37 C (Agilent Technologies). The slide was then dried
by centrifugation.
Scanning and data analysis:
The BCA–oligo array was scanned at a 3 micron resolution
on the high-resolution Agilent scanner. The scanner
measures the fluorescence intensity of two dyes simulta-
neously (wavelengths of 532 and 635 nm) from labeled
samples of nucleic acid bound to the BCA-1 test.
The scanned images were analyzed using Feature
Extraction software, and the graphic display of the data was
generated by Cytogenomics software (Agilent Technolo-
gies). Each oligo was positioned in the human genome in
accordance with NCBI Build 37 (UCSC hg19, February
2009). Cytogenomics software uses the Agilent ADM-2
algorithm. For these analyses, a probe was deemed to be
deleted if its standardized log2 ratio was \-0.2 and was
duplicated if its standardized log2 ratio was greater than 0.2.
The software segments displayed the data by grouping
together those probes which have a proximate position in
the genome and ratio averages which correspond to loss or
gain (Fig. 1).
Statistical analysis
In the first group of controls, patients were analyzed indi-
vidually for chromosomal aberrations. In the cohort of
patients with history of B-TCC, accuracy, sensitivity,
specificity and predictive values were calculated using as
endpoint the diagnosis of bladder tumor at cystoscopy
(qualified as positive). According to our previous model
(Larre et al.), the BCA-1 oligo array was defined as posi-
tive if at least one chromosomal arm aberration was
observed for the following loci: deletions (8p, 9p, 9q) or if
the percentage of aberrations on the 22 autosomes was
[2 %. The secondary endpoint was the aggressiveness
(2004 WHO classification) of the tumor on pathological
examination of the biopsy of the tumor. A high risk of high
grade (G3) for the biopsy sample was defined as positive if
the percentage of aberrations on the 22 autosomes was
[9 %. A synoptic table of chromosomal arms by aberra-
tions is given in Fig. 2, according to the 2004 WHO
aggressiveness classification of non-muscle-invasive
B-TCC. We looked for Pearson correlation between chro-
mosomal aberrations given in Fig. 2. Finally, BCA-1 pos-
itivity ([9 %) was calculated for presence and absence of
high-grade tumor on the biopsy. The distributions were
compared by logistic regression. Odds ratios (ORs) as a
measure of relative risk of high-grade disease and their
95 % confidence intervals (CIs) were estimated. Software
MedCalc12.7.0 (Acacialaan 22, B-8400 Ostend, Belgium)
was used for statistical analysis.
Results
Details of positive BCA-1 test were given in Table 1
according to history of urothelial tumors, result of cystos-
copy and result of histopathology on biopsy. First of all, we
World J Urol (2014) 32:551–557 553
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evaluated percentage of the false positive on the control
group (patients without history of B-TCC). Any chromo-
somal aberrations (any false positive) were identified in the
totality 30 control patients giving an accuracy of 100 %.
Secondly, we evaluated the accuracy (64 %), sensitivity
(95 %), specificity (51 %), positive predictive value (45 %
CI 95 % 34–55) and negative predictive value (96 % CI
95 % 86–98) of BCA-1 test considering positive cystoscopy
as endpoint. Aberrations on 9p/q and 8p were not correlated
together but correlated significantly with 17p/q aberrations
[Pearson correlation coefficient (p value) was respectively:
0.26 (p = 0.0017); 0.35 (p \ 0.0001); 0.65 (p \ 0.0001)
between locus 8p and 9p/q; locus 8p and 17p/q; locus 9p/q
and 17p/q].
Aberrations on 9p/q, 8p, combined aberrations at 8p or
9p/q and a ratio of [2 % of chromosomal arm aberrations
Fig. 1 Examples of normal profiles on chromosome 1, a gain on the 8q chromosome arm and a deletion on the 9p chromosome arm at the 9p21
locus
2004 WHO 1p 1q 2p 2q 3p 3q 4p 4q 5p 5q 6p 6q 7p 7q 8p 8q 9p 9q 1p 1q 11p 11q 12p 12q 13p 13q 14p 14q 15p 15q 16p 16q 17p 17q 18p 18q 19p 19q 2p 2q 21p 21q 22p 22q
PUNLMP
PUNLMP
LGPC 1 1 1
LGPC 1 1 1 1 1 1 1 1 1
LGPC 1
LGPC 1 1 1 1
LGPC 1 1 1 1 1
LGPC 1 1 1 1 1 1 1
LGPC 1 1 1 1 1 1 1
LGPC 1 1 1 1 1 1 1 1
LGPC 1 1 1 1 1 1 1 1
LGPC 1 1 1 1 1 1 1 1 1 1
LGPC 1 1
HGPC 1
HGPC 1 1 1
HGPC 1 1 1 1 1
HGPC 1 1 1 1 1
HGPC 1 1 1 1
HGPC 1 1 1 1 1 1 1
HGPC 1 1 1 1 1 1 1
HGPC 1 1 1 1 1 1
HGPC 1 1 1 1 1 1 1
HGPC 1 1 1 1 1 1 1 1 1 1
HGPC 1 1 1 1 1 1 1 1 1 1
HGPC 1 1 1 1 1 1 1 1 1 1
HGPC 1 1 1 1 1 1 1 1 1 1 1
HGPC 1 1 1 1 1 1 1 1 1 1 1 1 1
HGPC 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
HGPC 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
HGPC 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
HGPC 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
HGPC 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
HGPC 1 1 1
HGPC 1 1 1
HGPC 1 1 1 1
HGPC 1 1 1 1 1
HGPC 1 1 1 1 1 1
HGPC 1 1 1 1 1 1 1
HGPC 1 1 1 1 1 1 1 1
Fig. 2 Synoptic table of chromosomal arms by aberrations according to the 2004 WHO aggressiveness classification of non-muscle-invasive
B-TCC. PUNLMP papillary urothelial neoplasm of low malignant potential, LGPC and HGPC low-grade and high-grade papillary carcinoma
554 World J Urol (2014) 32:551–557
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were significantly associated with positive endoscopy with
an odds ratio and p value given in Table 2.
Thirdly, we looked for the relationship between the
diagnosis of high-grade disease on biopsy and the chro-
mosomal aberrations observed. The percentage of altera-
tions increased with the grade/stage of the tumor (Fig. 2).
A percentage value of [9 % for chromosomal arm aber-
rations on the 22 autosomes was associated with a high risk
of high-grade on histological examination of the biopsy
samples with an odds ratio of 53 (CI 95 % 7,417
p = 0.0002). According to our criteria, 100 % of high-
grade tumors were diagnosed, and the sensitivity, speci-
ficity, accuracy, positive predictive value and negative
predictive value were, respectively, 100, 75, 78 %; (39 %
CI 95 % 27–53) and (100 % CI 95 % 95–100).
Discussion
DNA alterations and cytogenetic aberrations have been
recognized to be closely linked to the natural history of
B-TCC. BCA-1 test is a robust assay based on DNA ana-
lysis of voided urines allowing to identify the main chro-
mosomal aberrations related to B-TCC natural history. We
show that BCA-1 has no false positive, in population of
patients with normal cystoscopy, normal cytology and no
history of B-TCC. BCA-1 detects all patients with a high-
grade disease recurrence of B-TCC and has a sensitivity of
95 % for the prediction of a positive cystoscopy for
patients followed for a history of B-TCC. The non-invasive
detection and monitoring of B-TCC recurrence remain a
challenge to reduce non-relevant invasive urinary explo-
ration using iterative cystoscopy and to replace voided
urinary cytology, which suffers from low sensitivity
(25–40 %) and observer-dependent variability. The detec-
tion of chromosomal instability at a specific locus has
previously been demonstrated, by us and others, to show a
high sensitivity (over 70 %) and specificity (over 70 %)
using multiplex microsatellite analysis or by CGH/SNP-
arrays [14, 15]. Imbalances on chromosomes 8p and 9p/q
have been reported as the most common events in non-
muscle-invasive B-TCC. We confirmed the observation of
Bulashevska et al. [16] who showed that 8p and 9p/9q
imbalances are mutually exclusive at early stages but
correlate together with 17p/q chromosomal aberrations
during progression. Chromosomes 8p and 9p/q aberrations
are identified in 78 % of tumor recurrences, including
100 % of high-grade disease cases. Only low-grade dis-
eases harbor rare and heterogeneous chromosomal imbal-
ances. Two papillary urothelial neoplasm of low malignant
potentials (PUNLMPs) were found to have any chromo-
somal aberrations on BCA-1, and this observation has been
previously reported by Chow et al. [17].
As false positives were not present in the control pop-
ulation without a history of B-TCC, patients with a history
of B-TCC ‘‘false positives’’ (36 % in our hand) could be
possible false negatives of cystoscopy (10–55 % from high
grade to atypia reported in the literature). Moreover,
according to the previous observations with microsatellite
analysis, positive cystoscopy could be postponed for
6–24 months after the detection of specific LOH in urine
[9].The commercially available FDA-approved Urovy-
sionTM test is also based on the detection of aneuploidy
(centromeric markers) for chromosomes 3, 7, and 17 and
the loss of the 9p21 locus, using multiprobe FISH, on cells
obtained from voided urine [18]. UrovysionTM test gives an
Table 1 Details of positive BCA-1 test according to history of uro-
thelial tumors, result of cystoscopy and result of histopathology on
biopsy Pearson correlation coefficients between chromosomal arm
aberrations at 8p, chromosome 9 and chromosome 17































PUNLMP 2 0 0
LGPC 11 11 8
HGPC 26 26 26
Table 2 Odds ratios (logistic regression) for 8p- or 9p-, 9q-, 8p- or








8p 8.7 3.3–23.1 \0.0001
9p 4.8 1.1–21.1 =0.0358
9q 15.1 1.5–152.2 =0.0207
8p or 9p/q 8.0 2.8–22.3 =0.0001
Ratio [2 % 5.7 1.1–29.3 =0.0367
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intermediate sensitivity of\70 % because it is limited to 2
endpoints: aneuploidy (using centromeric markers) and the
bladder-specific deletion at 9p21 locus, which occurs in
only approximately 25 % of cases. This fact has been
clearly demonstrated by Panzeri et al. [19]. Thanks to the
comparison of chromosomal aberrations in bladder cancer
by targeted FISH versus wide microarray-based CGH
analysis. Moreover, UrovysionTM needs to be coupled to
cytopathological examination, which is also time-con-
suming and has observer-dependent variability. Deletion at
chromosome 10q or gains on chromosomes 8q, 17q and
20q have been associated with progression using CGH
analysis of tissue [15, 20]. Moreover, chromosomal insta-
bility, quantified using the percentage of copy changes, has
been shown to be related to high-grade and invasive tumors
[15]. In our hands, the number (percentage) of chromo-
somal aberrations (over 9 %) is a strong marker for
determining which patients are at a high risk of having a
high-grade disease.
Other reports suggest that point mutation analysis of the
FGFR3, RAS and TP53 genes could be used on urine-
voided DNA to diagnose recurrent tumors [21, 22]. FGFR3
mutations are associated with recurrent, chromosome-sta-
ble and low-grade tumors, and they are mutually exclusive
from RAS and TP53 mutations associated with chromo-
some-unstable and high-grade tumors. The prevalence of
the more frequent mutations in exon 7 and exon 10 of the
FGFR3 gene [23] remains relatively low (\30 % for low-
grade B-TCC) and could be used to monitor follow-up
when a specific mutation has been previously identified in
the primary tumor.
The concept of the presence or absence of one or a small
number of molecular markers in a relevant diagnostic or
prognostic test in oncology contrasts with the heterogeneity
of solid tumors such as bladder carcinoma. However, at
this time, multiplex signatures are commercially available
for clinical practice.
Conclusion
High-throughput CGH-arrays [14], single-nucleotide
polymorphism arrays [15] or sequencing microarrays for
mitochondrial mutation detection [24] have demonstrated
their strong suitability for diagnostic/prognostic applica-
tions but remain too expensive for clinical practice. BAC-1
is the first commercially available microarray based on
CGH analysis that has been developed for clinical practice
(with the possibility to screen 8 patients on the same chip)
and could be used in an office-based outpatient setting.
Future trials using BAC-1 on a larger cohort and com-
parison of our results to other bladder tumor marker assays
may help us to identify the best and the most cost-effective
strategy to decrease discomfort and allow for more accu-
rate follow-up of patients with non-invasive B-TCC.
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